Associated tags: Research, Abcam, Drug discovery, Security (finance), Danaher Corporation, Sale, NYSE, Science
Locations: BELGIUM, SWITZERLAND, CHINA, US, UNITED STATES, MASSACHUSETTS, UNITED STATES OF AMERICA, CANADA, GERMANY, ITALY, NETHERLANDS, SPAIN, EUROPE, NORTH AMERICA, LONDON, FRANCE, AMERICAS, DISTRICT OF COLUMBIA, NEW YORK, WALES, BALA CYNWYD, PA, NY, NEW YORK CITY, LOUISIANA, HEWLETT, IRELAND, ASIA, ENGLAND, AUSTRALIA, JAPAN, MALAYSIA, SOUTH KOREA, THAILAND, UNITED KINGDOM, AUSTRIA, DANAHER, UK
CAMBRIDGE, England, March 18, 2024 /PRNewswire/ -- Abcam today announced the appointment of Markus Lusser as President.
Key Points:
- CAMBRIDGE, England, March 18, 2024 /PRNewswire/ -- Abcam today announced the appointment of Markus Lusser as President.
- A seasoned Danaher executive, Markus joins Abcam at a pivotal moment as the company transitions into the Danaher Life Sciences portfolio.
- Prior to joining Danaher, Markus was responsible for large global commercial organizations, including 20 years at Siemens Healthineers.
- As an experienced people leader, Markus is passionate about building and developing the skills and experience of his cross-functional teams.
CAMBRIDGE, England, March 18, 2024 /PRNewswire/ -- Abcam today announced the appointment of Markus Lusser as President.
Key Points:
- CAMBRIDGE, England, March 18, 2024 /PRNewswire/ -- Abcam today announced the appointment of Markus Lusser as President.
- A seasoned Danaher executive, Markus joins Abcam at a pivotal moment as the company transitions into the Danaher Life Sciences portfolio.
- Prior to joining Danaher, Markus was responsible for large global commercial organizations, including 20 years at Siemens Healthineers.
- As an experienced people leader, Markus is passionate about building and developing the skills and experience of his cross-functional teams.
Science,
Public Policy,
Government,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
Health,
Courts,
Registrar of Companies (India),
DHR,
Acquisition,
NYSE,
Transaction,
Court order,
Part,
Eastern Time Zone,
Scheme,
Danaher Corporation,
Registrar,
Court,
Companies Act 2006,
Cryptocurrency,
Abcam The circular in relation to the Scheme was published or made available to Scheme Shareholders on October 5, 2023 (the ‘Scheme Circular‘).
Key Points:
- The circular in relation to the Scheme was published or made available to Scheme Shareholders on October 5, 2023 (the ‘Scheme Circular‘).
- Abcam is pleased to announce that the Court has today issued the Court Order sanctioning the Scheme.
- The last day of trading in Abcam ADSs on Nasdaq is expected to be December 5, 2023, with trading in Abcam ADSs on Nasdaq being suspended by 8.00 a.m. (Eastern Time) on December 6, 2023.
- Capitalized terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Scheme Circular.
Retrieved on:
Friday, November 17, 2023
Professional Services,
Health,
Finance,
Research,
Science,
Biotechnology,
DHR,
Acquisition,
NYSE,
Transaction,
Business,
Scheme,
Eastern Time Zone,
Danaher Corporation,
High court,
Court,
Cryptocurrency,
Abcam The Court Hearing at which the Court will be asked to sanction the Scheme has been scheduled to be held on December 4, 2023.
Key Points:
- The Court Hearing at which the Court will be asked to sanction the Scheme has been scheduled to be held on December 4, 2023.
- An updated expected timetable of principal events is set out below.
- Capitalized terms in this announcement, unless otherwise defined, have the same meanings as set out in the Scheme Circular.
- by 8.00 a.m. (Eastern Time) on December 6, 2023
as soon as practicable after the Effective Time, and in any event not later than five Business Days after the Effective Time
Retrieved on:
Wednesday, December 6, 2023
The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the "Scheme") and the Scheme became effective in accordance with its terms on December 6, 2023.
Key Points:
- The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the "Scheme") and the Scheme became effective in accordance with its terms on December 6, 2023.
- As a result, Abcam has become an indirect wholly owned subsidiary of Danaher.
- Trading of Abcam ADSs on Nasdaq has been suspended.
- The consideration due to former Abcam shareholders will be settled pursuant to the terms of the Scheme and the consideration due to former Abcam ADS holders will be settled by the Depositary pursuant to the terms of the Deposit Agreement, in each case as further described in the shareholder circular relating to the Scheme, which was published by Abcam on October 5, 2023.
Research,
Finance,
Genetics,
Clinical Trials,
Professional Services,
Biotechnology,
Health,
Pharmaceutical,
Science,
Danaher,
Youth justice in England and Wales,
NYSE,
High court,
Court,
Mass meeting,
Acquisition,
Transaction,
Resolution,
Extraordinary general meeting,
Proxy,
Danaher Corporation,
DHR,
England,
Scheme,
Management,
Security (finance),
Cryptocurrency,
Abcam Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE: DHR) (‘Danaher’), today announced that its shareholders have approved the proposal for Danaher to acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction’).
Key Points:
- Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE: DHR) (‘Danaher’), today announced that its shareholders have approved the proposal for Danaher to acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction’).
- “With this approval, we are focused on moving swiftly toward transaction close and ensuring a successful transition to deliver maximum value to our shareholders, employees, and customers.”
“We are thrilled shareholders have overwhelmingly approved the Transaction.
- This outcome has arrived at the right time for Abcam to embark on the next chapter in its story within the Danaher family,” said Alan Hirzel, Chief Executive Officer of Abcam.
- The Resolution was therefore passed by the requisite majority of Abcam Shareholders.
Biotechnology,
Health,
Science,
Pharmaceutical,
Research,
CREST,
Glass Lewis,
Danaher,
BLUE,
Sale,
Citibank,
Youth justice in England and Wales,
High court,
EBITDA,
Court,
Mass meeting,
Acquisition,
Annual general meeting,
Glass,
ISS,
Scheme,
Union councils of Jessore District,
Management,
Security (finance),
Cryptocurrency,
Auction,
Abcam,
Proxy,
Equiniti Abcam plc (Nasdaq: ABCM) (‘Abcam,’ the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, announced that leading independent proxy advisor, Glass Lewis, recommended that Abcam shareholders vote “FOR” Danaher Corporation’s (“Danaher” or “DHR”) proposed acquisition of Abcam (the “Transaction”) ahead of its shareholder meetings on November 6, 2023.
Key Points:
- Abcam plc (Nasdaq: ABCM) (‘Abcam,’ the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, announced that leading independent proxy advisor, Glass Lewis, recommended that Abcam shareholders vote “FOR” Danaher Corporation’s (“Danaher” or “DHR”) proposed acquisition of Abcam (the “Transaction”) ahead of its shareholder meetings on November 6, 2023.
- Alan Hirzel, Chief Executive Officer of Abcam, said: “Following the publication of Glass Lewis’s recommendation on October 21, we’re pleased that both of the world’s leading proxy advisors support our board’s unanimous recommendation that shareholders vote ‘FOR’ the proposed sale to Danaher.
- Based on these factors, and absent a superior competing offer, we believe the Scheme warrants shareholder support at this time.
- As such, support for the proposed transaction is warranted.”
The Board of Directors and management of Abcam recommend shareholders vote “FOR” Danaher’s proposed acquisition of Abcam.
Retrieved on:
Tuesday, October 17, 2023
Biotechnology,
Science,
Health,
Research,
Institutional Shareholder Services,
Mass meeting,
Acquisition,
Annual general meeting,
BLUE,
High court,
Court,
CREST,
ISS,
Citibank,
Youth justice in England and Wales,
Danaher,
Sale,
Management,
Cryptocurrency,
Security (finance),
Auction,
Equiniti,
Proxy,
Abcam Abcam plc (Nasdaq: ABCM) (‘Abcam,’ the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announced that leading independent proxy advisor Institutional Shareholder Services (‘ISS’), recommended that Abcam shareholders vote “FOR” Danaher Corporation’s (‘Danaher’ or ‘DHR’) proposed acquisition of Abcam (the ‘Transaction’) ahead of its shareholder meetings on November 6, 2023.
Key Points:
- Abcam plc (Nasdaq: ABCM) (‘Abcam,’ the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announced that leading independent proxy advisor Institutional Shareholder Services (‘ISS’), recommended that Abcam shareholders vote “FOR” Danaher Corporation’s (‘Danaher’ or ‘DHR’) proposed acquisition of Abcam (the ‘Transaction’) ahead of its shareholder meetings on November 6, 2023.
- Alan Hirzel, Chief Executive Officer of Abcam, said: “We are pleased that ISS supports our board’s unanimous recommendation that shareholders vote “FOR” the proposed sale to Danaher.
- We are confident this transaction is in the best interests of Abcam and its shareholders, and will deliver an excellent outcome for Abcam’s employees and customers.
- Other materials related to the upcoming Abcam shareholder vote, including Abcam’s investor presentation are available at https://corporate.abcam.com/investors/danaher-abcam/ .
Abcam,
Danaher Corporation,
NYSE,
Kimco Realty,
Fraud,
AgeX Therapeutics,
Advertising,
Therapy,
RPT,
Sale,
KSL Capital Partners,
RPT Realty,
Security (finance),
Hersha Hospitality Trust If you are a RPT shareholder, click here to learn more about your rights and options .
Key Points:
- If you are a RPT shareholder, click here to learn more about your rights and options .
- Hersha Hospitality Trust (NYSE: HT)’s sale to affiliates of KSL Capital Partners, LLC for $10.00 per share.
- If you are a Hersha shareholder, click here to learn more about your rights and options .
- Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
Retrieved on:
Thursday, October 12, 2023
Professional Services,
Health,
Finance,
Research,
Science,
Biotechnology,
DHR,
Danaher Corporation,
NYSE,
Human,
BLUE,
Lazard,
LTM,
Cyprus Securities and Exchange Commission,
Transaction,
Independent director,
Morgan Stanley,
Environment,
Independent,
Volume-weighted average price,
Uncertainty,
Volume,
Discounted cash flow,
Sale,
Cryptocurrency,
Management,
Security (finance),
Pharmaceutical industry,
Auction,
Risk management,
Proxy,
Abcam We are writing to you today as the independent non-executive directors of Abcam’s Board of directors to affirm that this agreement was the result of a rigorous, fair and competitive sale process.
Key Points:
- We are writing to you today as the independent non-executive directors of Abcam’s Board of directors to affirm that this agreement was the result of a rigorous, fair and competitive sale process.
- We unanimously support this Transaction as we believe it is the best deal available and is in the best interests of Abcam and its shareholders.
- Ultimately, if this Transaction were not approved by shareholders, it is uncertain what path Abcam would be on next.
- We need your support to secure a positive outcome for all Abcam shareholders.
